Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Avalo Therapeutics filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $13.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 78.82% to $13.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.4 million, a 78.82% increase, with the full-year FY2025 number at $13.4 million, up 78.82% from a year prior.
  • Shares Outstanding (Diluted Average) hit $13.4 million in Q4 2025 for Avalo Therapeutics, down from $14.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $14.0 million in Q3 2025 to a low of $859381.0 in Q1 2024.